cyrilzakka/clinical-trials huggingface dataset:
The Effect of Facial Plane Blocks on Postoperative Recovery Quality in Hip Surgery

The aim of this study was to evaluate the effect of ultrasound-guided pericapsular nerve block, fascia iliaca compartment block, and femoral block on the quality of recovery as part of multimodal analgesia before hip surgery under spinal anesthesia.

Orthopedic procedures have become increasingly common in clinical practice. With the increasing elderly population, there have been significant developments in recent years in the field of perioperative pain management and anesthesia strategies for patients scheduled for hip surgery. Patients undergoing hip surgery may experience severe pain both postoperatively and during the positioning of the patient during surgery. This leads to increased sympathetic activation such as tachycardia and hypertension in patients, especially in the elderly population, and some undesirable complications due to the patients' existing comorbidities. Therefore, pain management strategies for patients undergoing hip surgery are based on a range of anesthesia techniques, including the use of opioids, neuraxial anesthesia (spinal, epidural, or a combination of them), nerve blocks, especially pericapsular nerve block (PENG), fascia iliaca compartment block (FICB) and femoral block). Reducing patients' pain and improving the quality of postoperative recovery has become increasingly important. The Quality of Recovery-15 (QoR-15) is a 15-question questionnaire validated to assess postoperative recovery. This questionnaire assesses patients' pain, physical comfort, physical independence, psychological support, and emotional status in the early postoperative period. The aim of this study was to evaluate the effect of ultrasound-guided PENG block, FICB block, and femoral block on the quality of recovery as part of multimodal analgesia before hip surgery under spinal anesthesia.

Eligibility Criteria:
Inclusion Criteria:

* elective hip fracture,
* 18-85 years
* American Society of Anaesthesiology (ASA) I-III

Exclusion Criteria:

* patients planned for general anesthesia
* with multiple fractures
* bleeding disorder
* peripheral neuropathy
* mental disorder
* local anesthetic allergy
* contraindications for spinal anesthesia (local infection, etc.)
* declining to give written informed consent
The Effects of Inspiratory Muscle Training on Diaphragm Thickness, Inspiratory Muscle Strength and Exercise Capacity in Individuals With Sarcopenia

Sarcopenia, according to EWGSOP2(European Working Group on Sarcopenia in Older People-2019), is a progressive and generalised skeletal muscle disorder that is associated with increased likelihood of adverse outcomes including falls, fractures, physical disability, and mortality. Changes in muscle strength and muscle mass that occur with aging are not only limited to the skeletal muscles surrounding the axial and appendicular skeleton, but also occur in the respiratory muscles. With aging, respiratory muscle strength decreases, muscle mass decreases, and respiratory functions decline. In sarcopenic individuals; maximum inspiratory pressure (MIP), maximum expiratory pressure (MEP) and diaphragm muscle thickness values were found to be significantly lower.

It is known that exercise is the most effective and valid way to treat sarcopenia. Considering the positive effects of IMT (Inspiratory Muscle Training) on both respiratory and physical parameters in the elderly population, we think that these changes can also be observed in sarcopenic individuals. Therefore, the aim of this study is to investigate the effects of inspiratory muscle training on diaphragm thickness, inspiratory muscle strength, and exercise capacity in sarcopenic individuals.


Eligibility Criteria:
Inclusion Criteria:

* People who are diagnosed with confirmed sarcopenia or severe sarcopenia according to EWGSOP2 (European Working Group on Sarcopenia in Older People-2019)
* Getting a score of 24 or higher on the mini-mental state test

Exclusion Criteria:

* Presence of chronic lung and/or cardiovascular disease
* Presence of severe orthopedic diseases which may affect participants' mobility
* Presence of uncontrollable hypertension and/or diabetes.
Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients.

The study is designed to investigate the safety, tolerability and efficacy of DG3173 in untreated acromegaly patients. Twenty patients received ascending single doses of DG3173 and one dose of octreotide, the current gold standard of medical therapy for acromegaly, with each patient receiving all doses of DG3173 as well as octreotide.


Eligibility Criteria:
Inclusion Criteria:

* Men, women of non childbearing potential or women of child bearing potential who either abstain from sexual intercourse, have a sterile partner or practice a medically approved double barrier method of contraception
* Diagnosis of acromegaly of pituitary origin
* Have age adjusted Insulin like Growth Factor 1 (IGF-1) concentrations ≥1.5 times the upper limit of normal range on two consecutive measurements in the 6 months prior to the first dosing day (including the measurement to be made at screening \[Visit 2\])
* Have a random hGH level of ≥5 µg/L in the 6 months prior to or at screening (Visit 2)
* Have given written informed consent
* Ability to comply with the requirements of the protocol of the study

Exclusion Criteria:

* Previous specific treatment for acromegaly in the 6 months prior to screening (Visit 2), including somatostatin analogues (SSAs), surgery, radiotherapy and pegvisomant
* Treatment with dopamine agonists in the 3 months prior to screening (Visit 2)
* Uncontrolled hypertension or orthostatic hypotension
* Type I diabetes mellitus, poorly-controlled type II diabetes mellitus (glycosylated haemoglobin \[HbA1c\]≥7.5%) and patients requiring insulin treatment
* Gallstones or gravel that could cause biliary obstruction
* Hyperprolactinaemia
* Participation in a clinical study within 60 days prior to screening (Visit 2)
* Receipt of blood, blood products or plasma derivatives 60 days prior to screening (Visit 2)
* Pregnancy or lactation
* A history of active alcohol abuse or drug addiction
* Positive viral serology screening result for hepatitis B surface antigen, antibodies to hepatitis C virus, or human immunodeficiency virus type 1 and 2
* Evidence or suspicion of tumour expansion
* Clinically significant abnormality in screening ECG
* Any clinically significant abnormal laboratory safety test (biochemistry, haematology and dipstick urinalysis) in the opinion of the Investigator
* Any disease which in the Investigator's opinion would exclude the patient from the study
Role of Reverse Transcriptase Inhibitors in the Treatment of Psoriasis

The investigators hypothesize that the inhibition of endogenous reverse transcriptase would: (1) reduce excess cytosolic DNA, stress initiating the inflammatory loop at the origin of psoriatic lesions, and (2) interrupt the loop and lighten lesions


Eligibility Criteria:
Inclusion Criteria:

* Patient suffering from plaque psoriasis for more than a year with at least one active skin lesion\> 4 cm2 in the photo-protected area.
* Patient using effective contraception (IUD, adapted pill, condom, etc.)
* The patient must have given their free and informed consent and signed the consent form
* The patient must be a member or beneficiary of a health insurance plan

Exclusion Criteria:

* Patient with another form or stage of psoriasis
* Patient on anti-cytokine treatment during the 6 months (180 days) before inclusion
* Patient under systemic treatment based on (1) corticosteroids, (2) antibiotics, (3) methotrexate, ciclosporin, soriatane, hydroxyurea, apremilast or (4) PUVA, (5) UVB, (6) vitamin D3 during the 4 weeks (28 days) before inclusion
* Patient on topical corticosteroid or retinoid treatment during the 2 weeks (15 days) before inclusion
* Patient with renal insufficiency; taking nephrotoxic agents (aminoglycosides, multiple or high doses of NSAIDs, etc.); creatinine clearance less than 50 ml / min; serum phosphorus below 1.0 mg / dl (0.32 mmol / l).
* Patient with active viral infection (HBV, HCV and HIV), or uncontrolled acute infection.
* Patient with hypersensitivity to one of the active substances or to any of the excipients (non-medicinal ingredients).
* Patient with uncontrolled coagulation disorder, history of keloid scars
* Patient with an allergy to local anesthetics; any condition likely to interfere at the time of the pre-inclusion visit, with the evaluation of the main objective such as eczema, psychiatric disorders
* Patient with uncontrolled systemic parameters The subject is participating in an interventional study, or is in a period of exclusion determined by a previous study
Diabetes Risk Evaluation and Microalbuminuria in Saskatchewan First Nations Peoples

This randomized controlled trial was designed to assess whether a community-based treatment strategy implemented by home care nurses would be effective in controlling hypertension in First Nations people with existing hypertension and type 2 diabetes.

Two community-based strategies for controlling hypertension in First Nations people with existing hypertension and diabetes were compared. In the intervention group, a home care nurse followed a predefined treatment algorithm of pharmacologic antihypertensive therapy. In the control group, treatment decisions were made by each subject's primary care physician. The primary outcome measure was the difference between the 2 groups in teh change in systolic blood pressure after 12 months.

Eligibility Criteria:
Inclusion Criteria:

* Age\>= 18 yr
* Type 2 diabetes mellitus
* Persistent hypertension (systolic pressure \>= 130 mmHg, diastolic pressure \>= 80 mm Hg, or both)

Exclusion Criteria:

* use of beta blocker
* women of child-bearing age not able to use a reliable method of birth control
* Connective tissue disorder
* Severe systemic or malignant disease
* Inability to follow the protocol
* Bilateral renal artery stenosis and other causes of secondary hypertension
* Serum creatinine level \> 250 micromol/L
* cerebrovascular even within 6 mo
* valvular heart disease
* unstable angina
* Myocardial infarction
* Revascularization procedure within 3 mo before study recruitment
* heart failure
* cardiac arrhythmia requiring medical treatment or heart block
* active hepatic disease
Leuprolide in Treating Adults With Hypogonadotropism

RATIONALE: Hypogonadotropism is an abnormal condition caused by decreased production of gonadotropins, a group of hormones that stimulate the parts of the reproductive system that produce and release eggs from the ovaries or sperm from the testicles. Leuprolide may stimulate the production of gonadotropins and be effective in increasing testosterone in men and inducing ovulation in women.

PURPOSE: Clinical trial to study the effectiveness of leuprolide in treating adults who have hypogonadotropism.

PROTOCOL OUTLINE: Male patients receive leuprolide subcutaneously every 5 days for up to one year and are followed at weeks 4, 6, 8, and 12, then every 2 months.

Female patients receive leuprolide subcutaneously on days 1, 6, and possibly 11. Patients are followed 2 months after the last injection.

Completion date provided represents the completion date of the grant per OOPD records

Eligibility Criteria:
PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

Diagnosis of hypogonadotropism

Men: Small testes, abnormal semen analysis, and subnormal plasma testosterone levels without an elevation in gonadotropin levels

Women: Amenorrhea and subnormal plasma estradiol levels, or lack of cornification of the vaginal mucosa without an elevation in gonadotropin levels OR Hypothalamic amenorrhea in normally estrogenized women with amenorrhea or oligomenorrhea and normal plasma free testosterone and gonadotropin levels

Patients with hyperprolactinemia eligible only if hypogonadotropism persists after correction of hyperprolactinemia by dopamine agonist therapy

--Prior/Concurrent Therapy-- At least 2 months since sex hormone treatment

--Patient Characteristics--

Other:

* Not pregnant
* No chronic systemic, metabolic, or endocrine disease
Anisometropia Amblyopia Improved by Perceptual Learning and Patching

To compare the effects of perceptual learning with patching on improving visual acuity and contrast sensitivity in payient with anisometropic amblyopia.

Patients with anisometropic amblyopia were randomized to patching or perceptual learning group. Corrected amblyopic logMAR visual acuity and contrast sensitivity function were measured at four-weekly intervals until visual acuity stabilized or amblyopia resolved. Improvement in visual acuity, contrast sensitivity, and the resolution of amblyopia were compared between groups.

Eligibility Criteria:
Inclusion Criteria:

* Anisometropia without strabismus
* An interocular acuity difference of at least 0.2 logMAR in children (3-7 years of age) or in older children and adult patients without a history of patching or atropine penalization
* All patients wore their spectacle at least one year

Exclusion Criteria:

* A history of prior spectacle correction
* A history of patching or optical penalization
* The existence of an ocular disease that could contribute to decreased visual acuity
* Learning difficulties
* The presence of strabismus
Improved Diagnostics for Paediatric Tuberculosis

Improved diagnostics for paediatric Tuberculosis

Research Question: To test the feasibility of TiKa system to reliably detect Mycobacterium tuberculosis in faeces of paediatric patients with Tuberculosis Study Design: Non-randomised diagnostic proof of concept feasibility study Study Participants: Patients with or suspected to have Tuberculosis

Eligibility Criteria:
Inclusion Criteria:

* Any patient under the age of 21 years with the following diagnosis for whom informed consent can be obtained will be offered to be included in the trial.

  * Latent tuberculosis
  * Culture confirmed Tuberculosis
  * Clinically suspected Tuberculosis

Exclusion Criteria:

* Any patient over 21
* Any child or adult/guardian unable to give informed consent
* Any persons under detention will not be included.
* Any patient who is unable to give a sample.
Acoustic Tribology Validation Study

Dairy-based beverages contain fat and sugars. As both contribute to the energy intake upon consumption, food industry strives to reduce these ingredients while maintaining the taste, texture and aroma properties of the beverages. A successful reduction of fat and sugar from drinks has still proven a great challenge since consumers have less preference for the mouth feel of reformulated beverages than for the regular beverages. Mainly because instrumental measures like rheology and traditional tribology do not entirely predict the experienced mouth feel, there is an interest in alternative correlates for mouth feel aspects related to fat and sugar perception. In a recent study it was demonstrated that vibrations produced during interaction between the tongue, palate and beverages during consumption are very sensitive to the amount of fat and texturizers in the beverage. The present study aims at clarifying that relation for a larger panel of human subjects, by systematically evaluating vibration spectra during consumption of dairy beverages that differ in fat content, sugar content or pH. Secondly, the correlation of vibration spectra (acoustic tribology) with mouth feel-related sensory properties and composition of fat deposits on the tongue will be assessed.


Eligibility Criteria:
Inclusion Criteria:

* Age 18-65 years
* Healthy set of teeth
* Ability to work with sensory descriptors for dairy products.
* Able to produce an acoustic signal that is larger than the background signal
* Voluntary participation
* Having given written informed consent
* Willing to comply with study procedures
* Willing to accept use of all encoded data, including publication, and the confidential use and storage of all data
* Willing to accept disclosure of the financial benefit of participation in the study to the authorities concerned

Exclusion Criteria:

* Wearing dentures
* Inability to comply with instructions for acoustic tribology
* A self-reported food allergy or sensitivity for ingredients of the test products
Neuropsychiatric Adverse Effects in Patients With Chronic Hepatitis C Treated by Direct Acting Antiviral Drugs

Neuropsychiatric adverse effects of direct acting antiviral drugs, especially Sofosbuvir and Daclatasvir combination therapy (with or without ribavirin) in patients with chronic hepatitis C , genotype four (the predominant genotype in Egypt).

Treatment of hepatitis C virus, a virus infecting over one hundred seventy million worldwide, has evolved over the last two decades and moved from interferon-alpha monotherapy to pegylated interferon-alpha in combination with ribavirin therapy. Despite enhanced sustained virological response rates, psychiatric illness remains a barrier to widespread hepatitis C virus treatment uptake due to the neuropsychiatric risks associated with interferon-alpha.The next generation of hepatitis C virus therapeutic agents is direct acting antivirals that still require the use of interferon-ribavirin combination therapy.

Poorly managed psychiatric illness can lead not only to treatment discontinuation,but also poor adherence to treatment and serious psychiatric sequels, such as suicide.

Data on neuropsychiatric adverse effects of direct acting antivirals is limited and predominantly derived from landmark clinical trials for boceprevir and telaprevir.These first generation direct acting antivirals are currently not in use due to their multiple side effects ,the need for concomitant interferon-alpha ,and there wide drug-drug interactions. Recently the treatment of hepatitis C virus has undergone a paradigm shift with the introduction of the second generation of direct acting antivirals. This interferon-free modality has brought about exceptional cure rates with sustained virological response exceeding ninety hundred percent, with better tolerability, minimized side effects and short duration of treatment . Of the current hepatitis C virus treatment regimens, the combinations of Sofosbuvir plus daclatasvir have shown a high efficacy rate in achieving sustained virological response in genotype one patients.

To the investigators' knowledge, the development of neuropsychiatric side effects with the use of these second generation direct acting antivirals in absence of interferon therapy, as well as the impact of the expected high sustained virological response to therapy on the psychiatric condition of patients with chronic hepatitis C (in absence of cirrhosis) have not been studied. Therefore, the purpose of this work is to evaluate the neuropsychiatric adverse effects of direct acting antivirals,especially Sofosbuvir and Daclatasvir combination therapy (with or without ribavirin) in patients with chronic hepatitis C, genotype four (the predominant genotype in Egypt).

Eligibility Criteria:
Inclusion Criteria:

* Patients with chronic hepatitis C only will be included.
* Patients who are eligible for treatment by DAAs only.

Exclusion Criteria:

* Cirrhotic patients will be excluded based on USS, APRI score index and FIB4 index.
* Hepatitis B infected patients will also be excluded.
* Patients with current or previous history of neuropsychiatric disorders will be excluded.
* Failure to obtain consent.
Personalized Diabetic Kidney Disease Risk Info to Initiate and Maintain Health Behavior Changes

We propose to pilot a telehealth approach to evaluate components of risk communication by:

1. Providing personalized tailored patient feedback to help initiate and maintain specific diabetic kidney disease (DKD)-related behaviors (e.g., medication adherence, weight, exercise, diet, smoking cessation) to reduce their risks.
2. Evaluating how this feedback can be incorporated into clinical care by examining 6 month patient outcomes.

Specific Aims are:

1. To evaluate the feasibility and acceptability of providing both patients and their provider feedback on individuals' DKD risk via the telehealth intervention and incorporating it into regular clinical practice.
2. If improvements in outcomes are found, to estimate the cost of the program in terms of the patient, provider, and overall costs of implementing the program.

We propose an innovative telehealth approach that has reduced antecedents of kidney disease, including poor blood pressure and glucose control, but has never been used to treat DKD. To mitigate the growing burden of DKD, these studies are designed to determine whether a potentially scalable, telehealth intervention effectively slows progression of DKD in a diverse US population and whether it is also cost-effective. The intervention simultaneously addresses medication management and behavioral therapies and education that seek to optimize adherence and self-efficacy. This proposed pilot trial will begin to evaluate if a multifactorial telehealth intervention may be effective in reducing progression of DKD.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of diabetes with progressive kidney disease

Exclusion Criteria:

* Metastatic cancer
* Dementia
* Psychosis
* No Access to phone
* Diagnosis of non-diabetic kidney disease
Registrar Performances in MIDP

This study aimed to determine whether registrar involvement in minimally invasive distal pancreatectomy (MIDP) was associated with adverse outcomes.

From January 2009 to March 2020, data of all consecutive patients requiring distal pancreatectomy in our public tertiary hospital were prospectively collected and retrospectively analyzed.

Registrars were progressively involved for MIDP since 2009 and their experience was: \< 5 open pancreatic resections, \< 5 MIDP and at least 30 advanced minimally invasive gastrointestinal resections.

Outcome of patients who underwent either distal pancreatectomy by the consultant or registrars were compared.

Our primary outcome was the conversion rate. The secondary outcomes were 90-days postoperative outcomes including CR-POPF defined and classified according to the 2016 ISGPF definition.

Eligibility Criteria:
Inclusion criteria:

- Patients who underwent minimally invasive distale pancreatectomy for benign or borderline pathology between 2009-2020

Exclusion criteria:

* open distal pancreatectomy
* minimally invasive distal pancreatectomy for pancreatic cancer
* 20 first consecutive patients operated on by the consultant (learning curve)